Oruka Therapeutics (ORKA) EV/EBIT: History & Chart

Oruka Therapeutics, Inc.(ORKA)

Biotechnology · Menlo Park, CA

$80.90-3.48 (-4.13%)

Delayed quote: Oct 6, 2026, 11:45 AM EDT

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Menlo Park, CA

68 employees

www.orukatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lawrence Otto Klein

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Oruka Therapeutics, Inc. (ORKA)	$4.88B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.86B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.92B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.75B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.70B	59.60x	192.46x	192.46x	192.46x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.08B	27.07x	27.45x	34.84x	44.16x
Option Care Health, Inc. (OPCH)vs ›	$4.65B	16.91x	15.96x	18.18x	22.57x
Erasca, Inc. (ERAS)vs ›	$5.13B	N/A	N/A	N/A	N/A
BillionToOne, Inc. (BLLN)vs ›	$4.62B	97.45x	157.20x	157.20x	157.20x
Scholar Rock Holding Corporation (SRRK)vs ›	$5.21B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Oruka Therapeutics, Inc. (ORKA)

$4.88B

N/A

Dianthus Therapeutics, Inc. (DNTH)vs ›

$4.86B

N/A

Mirum Pharmaceuticals, Inc. (MIRM)vs ›

$4.92B